How early audience insights reduce innovation failure
Learn how understanding audience habits first prevents costly innovation failures and gives companies a strategic advantage during uncertain times.
Launched with great promise in a climate of escalating drug costs, biosimilars have generated as many questions as answers for more than a decade.
Why does biosimilar adoption vary, even with significant discounts? What factors beyond price are encouraging or deterring biosimilar usage? And how do these factors affect the ultimate choice of a biologic vs biosimilar?
Published on the Pharmaceutical Market Europe (PME) December 2017 issue, our senior research manager, Adriƫnne discussed what prescribers are thinking when deciding between biologic vs biosimilar.
“To answer these questions, we surveyed physician key opinion leaders (KOLs) working in oncology and haematology across leading EU markets.
Survey discussions were designed to explore their perceptions and intentions regarding future use of MAb biosimilars. The results revealed consistent attitudes regarding several key issues that affect prescribing behavior. They include:
Be the first to receive the latest market research insights, tips from industry peers and exclusive content to help you influence decision behavior.
Learn how understanding audience habits first prevents costly innovation failures and gives companies a strategic advantage during uncertain times.
Discover how to maintain strategic insights during budget cuts. Learn three approaches for high-impact, cost-effective research in uncertain times.
SKIM is named a 2025 Global Most Loved Workplace! A proud recognition of our empowering, collaborative, and inspiring culture.
Transform market volatility into competitive advantage. Discover how to build strategic agility that responds purposefully without creating chaos.